# Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors

> **NCT02930993** · PHASE1 · UNKNOWN · sponsor: **China Meitan General Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Mesothelin Positive Tumors

## Interventions

- **BIOLOGICAL:** anti-mesothelin CAR T cells

## Key facts

- **NCT ID:** NCT02930993
- **Lead sponsor:** China Meitan General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-08
- **Primary completion:** 2018-08
- **Final completion:** 2019-08
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2016-10-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02930993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02930993, "Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02930993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*